BusinessActinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual MeetingBy Nasdaq OMXApr 11, 2018, 11:30 AM UTC
BusinessActinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on MyeloablationBy Nasdaq OMXFeb 8, 2018, 1:01 PM UTC
BusinessActinium Pharmaceuticals to Present at the BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 5, 2018, 9:15 PM UTC
BusinessActinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster ProductBy Nasdaq OMXFeb 1, 2018, 12:31 PM UTC
BusinessActinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual MeetingBy Nasdaq OMXDec 12, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology PlatformBy Nasdaq OMXNov 29, 2017, 12:32 PM UTC
BusinessActinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology PlatformBy Nasdaq OMXNov 14, 2017, 1:01 PM UTC
